white → yellow2 → green2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
DOC
2,5-Dimethoxy-4-chloroamphetamine
DOC is a psychedelic amphetamine of the DOx family, first synthesized in 1972 at the University of Alberta and later documented by Alexander Shulgin in PiHKAL (1991). It is characterized by its long duration, strong visual effects, and prominent stimulant properties. DOC is highly dose-sensitive and often sold on blotter paper.citation needed Its intense body load and potency make it particularly challenging for those inexperienced with psychedelics.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold0.5-1 mg
Light1-1.5 mg
Moderate1.5-2 mg
Strong2-4 mg
Heavy4+ mg
DOC is highly dose-sensitive and is often distributed on blotting paper. Its effects can last 12-24 hours, so a full day should be set aside; dosing early in the day is advisable.
Duration
Onset1-2 hours
Come Up2-3 hours
Peak6-12 hours
Offset2-8 hours
After Effects6-24 hours
Total12-24 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
The physical effects of DOC can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:
Cognitive
The cognitive effects of DOC are described by many as extreme mental stimulation combined with a powerful enhancement of a person's current mental state. The total sum of these cognitive components regardless of the setting generally includes:
Visual
Distortions
DOC presents a full and complete array of possible visual distortions which generally includes:
Enhancements
DOC presents a full and complete array of possible visual enhancements which generally includes:
Geometry
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equally rounded and angular in its corners, non-immersive in depth and consistent in intensity. At higher dosages this geometry is significantly more likely to result in states of level 8B visual geometry over level 8A.
Hallucinatory States
DOC and other substituted amphetamines produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. This holds particularly true in comparison to other substances within the phenethylamine family. These effects include:
Auditory
The auditory effects of DOC are common in their occurrence and exhibit a full range of effects which commonly includes:
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
DOC acts as a selective partial agonist at serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, with its psychedelic effects believed to be primarily mediated through activity at the 5-HT2A receptor,citation needed though the precise mechanisms by which this interaction produces the psychedelic experience remain unclear. Its selectivity for the 5-HT2 receptor subfamily has made it a commonly used tool in pharmacological research on these receptors. DOC also displays very weak agonist activity at trace amine-associated receptor 1 (TAAR1).
Pharmacokinetics
Controlled human pharmacokinetic parameters for DOC—oral bioavailability, time to peak concentration, clearance, and elimination half-life—have not been established in the literature summarized by WHO. Human case reports provide isolated concentrations rather than concentration-time profiles.citation needed Metabolism is not wholly unknown. Rat-urine studies identified O-demethylation at either the 2- or 5-position, with the resulting metabolites partly excreted as glucuronide and/or sulfate conjugates. In recombinant human-CYP and pooled human-liver-microsome experiments, CYP2D6 was the only isoenzyme identified in the principal O-demethylation step, although metabolite formation was small and this does not establish its quantitative contribution in humans in vivo.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineMAOIsMDMAMephedroneMescalineMXENBOMe compoundsPregabalin
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to the effects of DOC develops almost immediately after ingestion. Unlike many substances, tolerance does not build significantly without repeated use over a short period of time.
Baseline Reset
Full baseline tolerance is typically restored after approximately 7 days of abstinence from DOC.
Half Tolerance
Approximately 3 days after ingestion, tolerance is reduced to roughly half of its peak level.
Cross Tolerance
Serotonergic psychedelics (LSD, psilocybin, mescaline, DMT), Other phenethylamine psychedelics (2C-x series, DOx series), 5-HT2A agonists
Harm Potential
Addiction & Dependence
Psychological
Extremely LowDOC is not habit-forming and the desire to use it typically decreases with use, exhibiting a self-regulating quality. However, rodent studies have demonstrated reinforcing effects including conditioned place preference and self-administration similarly to methamphetamine.citation needed
Physical
Extremely LowDOC is not physically addictive and does not appear to produce physical dependence or withdrawal symptoms.citation needed
Toxicity
Cardiovascular
At overdose-level doses, DOC can cause significantly elevated heart rate, blood pressure, and severe vasoconstriction; individuals with pre-existing hypertension may be particularly at risk as the amphetamine-like pharmacology causes sharp increases in systolic blood pressure.citation needed
Pulmonary
Pulmonary edema was noted in a fatal DOC overdose case, though data is limited to individual case reports rather than systematic study.1
Psychosis Risk
Psychosis, delusions, and bizarre or violent behavior may occur at high doses or in overdose scenarios. The substance's high dose sensitivity and unusually long duration increase the risk of adverse psychological reactions, particularly in those without extensive hallucinogen experience.citation needed
Seizure Risk
Seizures have been associated with DOC use in medical literature and may occur at high doses or in overdose situations.citation needed
History & Culture
Discovery and Synthesis
DOC was originally synthesized by Ronald Coutts and Jerry Malicky at the University of Alberta in Canada.citation needed Their work describing the compound was published in the scientific literature in 1973 as part of research into analogues of DOM and related substituted
Legality
International
DOC is listed in Schedule I of the Convention on Psychotropic Substances of 1971. It is not listed under the 1961 Single Convention on Narcotic Drugs. It is not listed under the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
By Country
Illegal28
United StatesIllegal (analog/blanket ban)Not federally scheduled, but may be prosecuted as an analogue of DOM or DOB under the Federal Analogue Act when sold for human consumption or possessed with intent to ingest. Specifically listed as Schedule I in Florida state law.
By state
Across the 50 states, D.C., and the permanent territories, most jurisdictions treat DOC consistently with federal control; listed entries record independently verified differences in state classification or coverage.
AlabamaIllegalAlabama Administrative Code r. 420-7-2-.01, Schedule I71
DOC is listed in Alabama's Schedule I controlled-substances schedule. Alabama therefore controls DOC by a named state listing rather than only through case-specific federal analogue analysis.
ArizonaIllegalArizona defines methoxyphenethylamine mimetic substances as dangerous drugs; DOC falls within that generic definition through its substituted 2,5-dimethoxyphenethylamine structure. Arizona separately prohibits knowingly possessing or using a dangerous drug.
FloridaIllegalFla. Stat. § 893.03(1)(c)7374
Florida lists DOC in Schedule I as 4-chloro-2,5-dimethoxyamphetamine. The named Schedule I listing controls DOC independently of federal analogue analysis.
IdahoIllegalIdaho Code § 37-2705(d)(1)75
Idaho places DOC in Schedule I through its hallucinogenic-substances definition for dimethoxyphenethylamine derivatives. The statute specifically names DOC as an included example, establishing direct state Schedule I control.
IowaNot scheduledDOC is not named in Iowa's statutory Schedule I hallucinogen list. The list includes several related dimethoxyamphetamines, including DOB, DOM, and DOET, but does not include 4-chloro-2,5-dimethoxyamphetamine. Iowa's reviewed Chapter 124 schedule text does not provide a general controlled-substance-analogue classification for DOC.
MinnesotaIllegalMinn. Stat. § 152.02, subd. 2(d)(27)78
Minnesota lists DOC by name as a Schedule I hallucinogenic substance. The listing applies to 4-chloro-2,5-dimethoxyamphetamine and identifies DOC as an alternate name. This express state Schedule I listing differs from the federal baseline, where DOC is not expressly listed.
NebraskaIllegal
New MexicoIllegal16.19.20.65(E)(89) NMAC81
New Mexico's current Schedule I rule expressly lists DOC as 2,5-dimethoxy-4-chloroamphetamine among hallucinogenic substances. The rule applies to materials, compounds, mixtures, or preparations containing the listed substance, subject to its stated exemptions and scheduling qualifications.
North CarolinaIllegalN.C. Gen. Stat. § 90-89(8)82
North Carolina places substituted phenethylamines in Schedule I. That statutory class reaches a phenylethan-2-amine with two alkoxy substitutions and an alpha alkyl substitution, which includes DOC.
OklahomaIllegalOkla. Stat. tit. 63, § 2-204(C)(67)83
DOC is specifically listed as a Schedule I controlled dangerous substance in Oklahoma. The listing gives it a state controlled-substance status independent of the stated federal baseline.
South DakotaIllegalS.D. Codified Laws § 34-20B-1484
DOC is specifically listed as a Schedule I hallucinogenic substance in South Dakota. The state listing classifies the substance as controlled independently of the stated federal baseline.
VermontIllegal
VirginiaIllegalVa. Code § 54.1-3446(3), Schedule I87
DOC is a Schedule I controlled substance in Virginia. The Schedule I hallucinogenic-substances list expressly names 2,5-dimethoxy-4-chloroamphetamine and identifies DOC as its other name.
AustraliaIllegalAs of 1 June 2026, the Poisons Standard classifies DOC as a Schedule 9 prohibited substance through its entry for alkoxyamfetamines and substituted alkoxyamfetamines. Schedule 9 restricts manufacture, possession, supply and use to approved medical, scientific, analytical, teaching or training purposes under Commonwealth and State or Territory health-authority arrangements. At the Commonwealth border, the Customs (Prohibited Imports) Regulations 1956 specifically list DOC as a Schedule 4 drug, and importation requires both a licence and permission.
AustriaIllegalDOC is listed in Anhang V.1 of Austria's Suchtgiftverordnung and is treated as a Suchtgift under the Suchtmittelgesetz. Unauthorized acquisition, possession, production, transport, import, export, offering, supply, or procurement of DOC is punishable under section 27 of the Suchtmittelgesetz. The Suchtgift-Grenzmengenverordnung sets a 1.0-gram large-quantity threshold for DOC.
BelgiumIllegal (analog/blanket ban)Royal Decree of 6 September 2017 regulating narcotic drugs and psychotropic substances, Annex IVa, Figure 1 (1-phenylpropan-2-amine derivatives), and Article 61011
DOC is not named in the decree's schedules, but its 2,5-dimethoxy-4-chloroamphetamine structure is a substituted 1-phenylpropan-2-amine within the generic class in Annex IVa. The current consolidated decree subjects Annex IV substances to the activity-authorisation regime; that authorisation is personal and limited to scientific or medical purposes.
CanadaIllegal
ChinaIllegalNon-pharmaceutical Narcotic and Psychotropic Drugs Directory (2025), item 24, as reproduced in the current Shenzhen Public Security Bureau directory; Regulation on the Control of Narcotic Drugs and Psychotropic Drugs (current consolidated text, Articles 2, 3, 4 and 10); 28 July 2025 three-department directory notice.171819
DOC is currently listed in China's operative 2025 Non-pharmaceutical Narcotic and Psychotropic Drugs Directory at item 24, as confirmed by the Shenzhen Public Security Bureau page updated in July 2026. The catalogue note extends the listing, unless otherwise specified, to possible salts, stereoisomers and their salts. It is a non-medicinal controlled substance, not a Category I medicinal psychotropic substance: Article 3 reserves Category I/II terminology for medicinal psychotropics. The ordinary rule under Article 4 prohibits production, commercial operation, use, storage and transport. Experimental research is a regulated pathway only when the Article 10 purpose, safety-management and two-year compliance conditions are met and the required approval is obtained. Import and export are handled under applicable laws under Article 2. The 2025 notice records that the latest directory took effect on publication and repealed the former supplementary directory.
Czech RepublicIllegalGovernment Regulation No. 463/2013 Coll., Annex 4 (as amended by Government Regulation No. 243/2015 Coll.)222324
DOC has been listed in Seznam č. 4 psychotropních látek under Government Regulation No. 463/2013 Coll. since 1 October 2015, when Government Regulation No. 243/2015 Coll. replaced Annex 4. Under section 3(2) of Act No. 167/1998 Coll., substances in Annex 4 and preparations containing them may be used only for limited research, scientific and very limited therapeutic purposes specified in a handling permit. Production, storage, supply, use, purchase and sale are regulated forms of handling; a transfer or sale may be made only to a person authorized to handle the substance.
DenmarkIllegalDanish Regulation on Euphoriant Substances (BEK 405/2026)25
The regulation is marked Gældende and dated 26 March 2026; DOC is expressly listed on List B, subject to the regulation's authorization exceptions.
FinlandIllegalValtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista 543/200826
Possession, production, and sale are prohibited under national drug legislation.
IndiaIllegalNarcotic Drugs and Psychotropic Substances Act, 1985, section 2(xxiii), section 8(c), and Schedule entry 110ZO (inserted by S.O. 1275(E), 23 March 2021)28
DOC is directly listed as "4-Chloro-2,5-dimethoxyamfetamine" at entry 110ZO in the Schedule of psychotropic substances to India's Narcotic Drugs and Psychotropic Substances Act, 1985. The official India Code consolidation attributes that entry to Notification S.O. 1275(E), dated 23 March 2021. Section 2(xxiii) defines a substance in that Schedule as a psychotropic substance, and section 8(c) prohibits the specified operations involving it except for medical or scientific purposes as provided by the Act, rules, or orders and any applicable licence, permit, or authorisation. The listing names DOC itself, rather than only an analogue, constituent, or specified product.
IndonesiaIllegalDOC is expressly listed as 1-(4-Kloro-2,5-dimetoksifenil)propan-2-amina in the Group I narcotics schedule annexed to Peraturan Menteri Kesehatan Nomor 15 Tahun 2025. The regulation defines Group I narcotics as substances usable only for scientific development and not for therapy. It was promulgated on 28 November 2025, entered into force that day, and repealed Peraturan Menteri Kesehatan Nomor 7 Tahun 2025; the Ministry of Health's official legal-information database records it as in force.
IrelandIllegal (analog/blanket ban)Misuse of Drugs Act 1977, section 3; Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022), Schedule 1, paragraph 1(l); Misuse of Drugs Regulations 2017, regulation 5 and Schedule 1 as substituted by S.I. No. 210/20223132333435
DOC is not named individually; its 2,5-dimethoxy and 4-chloro ring substitutions place it within the Schedule 1 definition for a substance structurally derived from alpha-methylphenethylamine with alkoxy or halo ring substituents. The 2022 Designation Order applies section 13(1) of the Misuse of Drugs Act 1977 to that Schedule 1 class; the Act prohibits possession of a controlled drug, and the Regulations prohibit production, supply, importation, and exportation subject to their specified authorities and exceptions. The current Schedule 1 derives from the 2022 substitution, and the later 2025 amendments affected paragraph 1(a), not paragraph 1(l).
IsraelIllegalDangerous Drugs Ordinance [New Version], 5733-1973, section 1 and First Schedule, Part B, Sign B, item 1 (amphetamine, including isomers and structural derivatives unless expressly excluded), and sections 6, 7, 13 and 19A; Notice of Dangerous Drugs (Amendment of the First Schedule to the Ordinance), 5785-2025, Gazette 11879, p. 1819.36373839
The current consolidated First Schedule expressly includes amphetamine isomers and structural derivatives unless expressly excluded, and separately defines structural derivative by chemical-group substitution/replacement or removal. DOC's PubChem identity is an alpha-methylphenethylamine with 2,5-dimethoxy and 4-chloro ring substitutions, so the classification follows the schedule's generic text; the 2013 urgent declaration has expired. The 2025 notice does not name DOC or create an exclusion. The Ordinance provides for authorization, licensed handling and medical exceptions; not every circumstance or formulation is unauthorized.
JapanIllegalDOC (1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine) and its salts are designated as narcotics (麻薬) by Japan's Cabinet Order Designating Narcotics, Narcotic Raw Material Plants, Psychotropic Substances and Narcotic and Psychotropic Substance Raw Materials. The Narcotics and Psychotropics Control Act restricts manufacture, transfer, and possession of narcotics to licensed or specifically authorised persons; unlicensed possession, manufacture, and sale or transfer are prohibited.
LatviaIllegalRegulations Regarding Classification of Narcotic and Psychotropic Substances and Medicinal Products43
Classified as a Schedule I controlled substance under Latvian law.
NetherlandsIllegalOpiumwet, Lijst I44
DOC (4-chloor-2,5-dimethoxyamfetamine) is expressly included in Lijst I of the Opiumwet. Article 2 prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing, and manufacturing List I substances, subject to the Act's authorized exemptions and dispensations.
New ZealandIllegalMisuse of Drugs Act 197545
Controlled as an amphetamine analogue under Schedule III (Class C) of New Zealand's controlled substances legislation.
NorwayIllegalForskrift om narkotika46
DOC is included in Norway's national narcotics list as 4-chloro-2,5-dimethoxyamphetamine. The regulation treats listed substances as narcotics under the Norwegian control regime.
PolandIllegalRozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 147484950
DOC is listed as 2,5-dimetoksy-4-chloroamfetamina in Group I-P of Annex 1 to the Health Minister's regulation on psychotropic substances, narcotic drugs, and new psychoactive substances. Group I-P psychotropic substances may be used only for research. Possession contrary to the Act is punishable by imprisonment for up to three years, and unlawful manufacture or supply is subject to separate criminal penalties under the Act on Counteracting Drug Addiction.
SingaporeIllegalMisuse of Drugs Act 197351
DOC is a Class A controlled drug in Part I of the First Schedule to Singapore's Misuse of Drugs Act. The Act criminalises unauthorised possession, trafficking, manufacture, import, export, and consumption of controlled drugs.
SpainIllegalReal Decreto 2829/1977, de 6 de octubre52
DOC is included in Lista I of Spain's psychotropic-substances schedules. Lista I substances are subject to the decree's control and prohibition regime.
SwedenIllegalDOC is listed as 4-klor-2,5-dimetoxiamfetamin in Förteckning I of the Swedish Medical Products Agency's current consolidated narcotics schedule. The schedule states that Förteckning I covers substances that normally have no medical use; the Government's current Ordinance (1992:1554) identifies DOC as a substance deemed narcotic under the Narcotic Drugs Penal Law, which criminalises unauthorised possession, use, transfer, manufacture, and other handling of narcotics.
SwitzerlandIllegalDOC is listed in Verzeichnis d of the Betäubungsmittelverzeichnisverordnung. Verzeichnis d is Switzerland's category of prohibited controlled substances. Unauthorised manufacture, sale, possession, storage, and acquisition of narcotics are punishable under the Narcotics Act; federal exceptions are available for specified research, medicine-development, and limited medical uses.
ThailandIllegalNotification of the Ministry of Public Health Re: Specifying Names of Narcotics in Category 1, B.E. 2565 (2022)606162
DOC is expressly listed as 4-chloro-2,5-dimethoxyamphetamine in Category I of the Ministry of Public Health notification made under Thailand's Narcotics Code. The notification was published on 25 October 2022 and took effect 30 days later. Unauthorized production, import, export, sale, or possession of a Category I narcotic is punishable by up to 15 years' imprisonment and a fine of up to 1,500,000 baht.
TurkeyIllegal (analog/blanket ban)26/1/2015 tarihli ve 2015/7238 sayılı Bazı Maddelerin 2313 Sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun Hükümlerine Tabi Tutulması Hakkında Karar63
Classified as a controlled drug. Illegal to possess, produce, supply, or import.
Controlled / restricted1
ColombiaRestrictedResolution No. 000116 of 2026 took effect on 27 January 2026 and replaced the technical annexes adopted by Resolution No. 315 of 2020. Its revised Technical Annex 1 lists DOC (2,5-Dimetoxi-4-cloroamfetamina) at No. 194 in Lista Nacional, the national list of substances subject to special control and fiscalization. This is a national control designation, not a Green List I psychotropic designation.
Legal / decriminalized1
ItalyDecriminalizedDecreto del Presidente della Repubblica 9 ottobre 1990, n. 30940
DOC is entered in Tabella I of Italy's consolidated drug law. Unauthorised production and supply are criminal offences, while personal-use conduct is addressed through the decree's administrative-sanction regime.
References
Source Pages
Citations
- World Health Organization Expert Committee on Drug Dependence. (2019). Critical Review Report: DOC (4-Chloro-2,5-dimethoxyamfetamine). World Health Organization. https://researchonline.ljmu.ac.uk/id/eprint/11444/1/ECDD42_DOC.pdf12
- World Health Organization ECDD. ecddrepository.org (n.d.). https://ecddrepository.org/sites/default/files/2023-04/final_doc.pdf1
- Ronald T. Coutts, & Jerry L. Malicky. (1973). The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM). https://doi.org/10.1139/v73-2101
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html1
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F1996B03651/2026-03-26/2026-03-26/text/original/epub/OEBPS/document_1/document_1.html1
- Suchtgiftverordnung, Anhang V. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053&Anlage=51
- Suchtgiftverordnung, Anhang V. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053&Paragraf=11
- Suchtgiftverordnung, Anhang V. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011040&Paragraf=271
- Suchtgiftverordnung, Anhang V. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011056&Anlage=11
- Royal Decree of 6 September 2017 regulating narcotic drugs and psychotropic substances, Annex IVa, Figure 1 (1-phenylpropan-2-amine derivatives), and Article 6. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
31 July 2026
Lyrea · Updated the article
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DOC article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.